MILFORD, Mass., Dec. 17, 2013 /PRNewswire/ -- SeraCare Life Sciences, a provider of high quality biological materials that help optimize diagnostic performance, reliability and repeatability across the IVD lifecycle, today announced a new CMV DNA AccuSpan™ Linearity Panel. This new offering is a nine member panel made from serial dilutions of a cultured virus with established reactivity for CMV DNA.
Cytomegalovirus (CMV) is one of the herpes viruses that infect cells and cause cellular enlargement. CMV infections are usually asymptomatic in healthy individuals but are considered a threat to unborn babies, infants and those who have weakened immune systems or are undergoing organ transplants.
The CMV DNA AccuSpan™ Linearity Panel consists of seven positive members representing serial log dilutions of cultured virus in CMV DNA negative diluent, one negative member prepared from the diluent, and one member of diluent to perform additional dilutions as desired. The results of the CMV test were calibrated to the WHO International CMV Standard for Nucleic Acid Amplification Techniques and show a nearly 1:1 linearity.
"Being able to offer this new, robust linear challenge panel for quantifying CMV viral load means our end users can obtain improved data that will ultimately aid in their research," said Christopher Long, Product Manager at SeraCare. "And because regulatory bodies require dilutions performed in a lab be made with the same diluent as the panel, we knew it was imperative to add an extra diluent so end users could perform sensitivity challenges on their own, in their labs."
About SeraCare Life Sciences, Inc.
SeraCare, a portfolio company of Linden Capital Partners, works with diagnostics researchers, IVD manufacturers, and clinical laboratories to shape the future of medical diagnostics. Our innovative portfolio includes ACCURUN® quality controls, research panels, KPL™ antibodies and immunoassay reagents, SeraCon™ processed plasma, specialty human blood products, and Complete BioCollections™ materials. SeraCare helps bridge the gap between today's diagnostic solutions and tomorrow's emerging technologies.
About Linden Capital Partners
Linden Capital Partners is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden's strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden currently has investments in middle market platforms in the products, distribution, and services segments of healthcare. For additional information about Linden, please refer to the firm's website at www.lindenllc.com.
SOURCE SeraCare Life Sciences, Inc.